Please assess the completion status of the following clinical trial:

Trial Title: Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed high-grade prostatic intraepithelial neoplasia~  * Diagnosed within the past 6 months~* No evidence of prostate cancer within the past 6 months~* No evidence of palpable nodules on digital rectal exam~* Prostate specific antigen ≤ 10 ng/mL within the past 3 months~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* SGOT and SGPT ≤ 1.5 times upper limit of normal~Renal~* No uncontrolled renal failure~* No cancer-related hypercalcemia or kidney stones within the past 5 years~Cardiovascular~* No uncontrolled coronary artery disease~* No uncontrolled congestive heart failure~Other~* Prior malignancy allowed provided patient was curatively treated and has been disease-free for an appropriate time period for the specific cancer~* No known HIV positivity~* No active infection~* No major depression or suicidal ideation~* No other condition that would preclude study compliance~* No other uncontrolled medical condition~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for any malignancy~Endocrine therapy~* At least 2 weeks since prior and no concurrent finasteride (Prosear® or Propecia®) or other androgen suppressor~* No concurrent corticosteroids~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* At least 2 weeks since prior phenytoin or phenobarbital~* At least 2 weeks since prior ketoconazole~* No concurrent administration of any of the following:~  * Magnesium-containing antacids~ * Thiazide diuretics~ * Calcium supplements~ * Digoxin~ * Herbal supplements~ * Pharmacological doses of cholecalciferol (vitamin D) or its derivatives

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
- Arm II (Type: OTHER): Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).